Search - tctmd.com

Displaying 1 - 20 of 151

Sort: Relevancy | Date

News Daily News

Advanced HF in Finland: Costs, Survival Diverge for Elective vs Urgent LVAD

Caitlin E. Cox

March 06, 2026

News Conference News THT 2026

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

Todd Neale

March 04, 2026

Presentation THT Abstracts 2026

Echocardiographic Assessment of Progressive Dyspnea in an LVAD Patient

Presenter: Kevin O’Gorman

March 02, 2026

Presentation THT Abstracts 2026

Digoxin and Fish Oil in LVAD Patients: A Retrospective Analysis on GI Bleed Prevention

Presenter: Alex Caplan

March 02, 2026

Presentation THT Abstracts 2026

Running Out of Options: When LVAD Complications Limit MCS Strategies

Presenter: Madison Rose-Malkamäki

March 02, 2026

News Conference News THT 2026

THT 2026: What to Expect in Boston

Todd Neale

February 23, 2026

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Daily News

Care Gaps for Women With Cardiogenic Shock Merit Action: SCAI

L.A. McKeown

June 05, 2025

Presentation THT 2025

Impact of Preoperative Temporary Mechanical Circulatory Support on Durable LVAD Outcomes: An Analysis of the Society Of Thoracic Surgeons National Intermacs Database

Presenter: Manreet Kanwar

February 13, 2025

Presentation THT 2025

Impact of Age on Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial

Presenter: Nir Uriel

February 12, 2025

Presentation THT 2025

Barostim With Durable Left Ventricular Assist Device (LVAD) Therapy

Presenter: Kanika Mody

February 12, 2025

Presentation THT 2025

HF Etiology and the Sustainability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 12, 2025

Presentation THT 2025

The Use of Cardiac Contractility Modulation(CCM) and Durable Left Ventricular Assist Device (LVAD) for Patients With Class IV CHF

Presenter: Kanika Mody

February 12, 2025

Presentation THT 2025

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

Presenter: Stavros Drakos

February 12, 2025

Presentation THT 2025

ARIES Implementation in LVAD Practice

Presenter: Nir Uriel

February 12, 2025

Presentation THT 2025

DOACS in LVAD: Should We, Should We Not?

Presenter: Palak Shah

February 12, 2025

Presentation THT 2025

Eliminating the Driveline: The Ultimate Solution

Presenter: Melana Yuzefpolskaya

February 12, 2025

Presentation THT 2025

Remote Monitoring in LVAD Patients

Presenter: Gabriel Sayer

February 12, 2025

Presentation THT 2025

Treating Aortic Regurgitation in LVAD Patients - Who, When and How

Presenter: Torsten Vahl

February 12, 2025

Presentation THT 2025

Recovery From Advance HF: Candidate Selection, Durability and Magnitude of Opportunity

Presenter: Stavros Drakos

February 12, 2025

Advertisement

Advanced HF in Finland: Costs, Survival Diverge for Elective vs Urgent LVAD

Optimal BP After HeartMate 3 LVAD May Be Higher Than Previously Thought

Echocardiographic Assessment of Progressive Dyspnea in an LVAD Patient

Digoxin and Fish Oil in LVAD Patients: A Retrospective Analysis on GI Bleed Prevention

Running Out of Options: When LVAD Complications Limit MCS Strategies

THT 2026: What to Expect in Boston

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Care Gaps for Women With Cardiogenic Shock Merit Action: SCAI

Impact of Preoperative Temporary Mechanical Circulatory Support on Durable LVAD Outcomes: An Analysis of the Society Of Thoracic Surgeons National Intermacs Database

Impact of Age on Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial

Barostim With Durable Left Ventricular Assist Device (LVAD) Therapy

HF Etiology and the Sustainability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

The Use of Cardiac Contractility Modulation(CCM) and Durable Left Ventricular Assist Device (LVAD) for Patients With Class IV CHF

Impact of HF Pharmacological Therapy on the Durability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis

ARIES Implementation in LVAD Practice

DOACS in LVAD: Should We, Should We Not?

Eliminating the Driveline: The Ultimate Solution

Remote Monitoring in LVAD Patients

Treating Aortic Regurgitation in LVAD Patients - Who, When and How

Recovery From Advance HF: Candidate Selection, Durability and Magnitude of Opportunity

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content